Chrostek L, Cylwik B, Panasiuk A, Brodowska-Adamusiak D, Gruszewska E

Language: English
References: 16
Page: 150-154
PDF size: 74.33 Kb.

ABSTRACT

Objective. There are evidences that the changes in glycosylation and sialylation of proteins and lipids play an important role in the pathogenesis and progression of various liver diseases. The aim of this study was to evaluate the changes in the sialylation of serum lipids measured by the level of lipid-bound sialic acid (LSA) in liver diseases of different etiologies. Materials and methods. Tested group consisted of 303 patients suffering from liver diseases: alcoholic and non-alcoholic cirrhosis, chronic non-viral hepatitis, toxic hepatitis, chronic viral C and B hepatitis, autoimmune hepatitis, primary liver cancer, liver cancer and cirrhosis (mixed group), acute hepatitis B, primary biliary cirrhosis and fatty liver. LSA was determined by the method of Katopodis and co-workers. Results. There were significant differences in the serum LSA concentrations between liver diseases of different etiologies. The level of LSA in liver tumors was higher than that in both types of cirrhosis: alcoholic and non-alcoholic. In turn, LSA level in non-alcoholic cirrhosis was lower than in toxic hepatitis and mixed group. There was no difference in LSA concentration between tumor and mixed group. Similarly to LSA, AFP level in tumor group was also higher than that in both cirrhotic groups, but there was no difference in AFP concentration between tumor and mixed group. Conclusions. The sialylation of serum lipids alters in liver diseases of different etiologies. Given the importance of glycans in biological systems we can speculate that the changes in lipids sialylation play an important role in liver pathology, especially in primary cancer, cirrhosis and toxic hepatitis.

REFERENCES

1. Schauer R, Kelm S, Reuter G, Roggentin P, Shaw L. Biochemistry and role of sialic acid. In: Rosenberg A (ed.). Biology of the sialic acids. New York: Plenum Press; 1995, p. 7-47.

2. Millar JS, Anber V, Shepherd J, Packard CJ. Sialic acid-containing components of lipoproteins influence lipoproteinproteoglycan interactions. Atherosclerosis 1999; 145: 253-60.

3. Marmillot P, Rao MN, Liu QH, Lakshman MR. Desialylation of human apolipoprotein E decreases its binding to human high-density lipoprotein and its ability to deliver estrified cholesterol to the liver. Metabolism 1999; 48: 1184-92.

4. Sillanaukee P, Ponnio M, Jaaskelainen IP. Occurrence of sialic acid in healthy humans and different disorders. Eur J Clin Invest 1999; 29: 413-25.

5. Blomme B, Van Steenkiste C, Callewaert N, Van Vlierberghe H. Alteration of protein glycosylation in liver diseases. J Hepatol 2009; 50: 592-603.

6. Senn JH, Sellin S, Fitzke E, Stehle T, Häussinger D, Wieland H, Gerok W. Biosynthesis and excretion of gangliosides by isolated perfused rat liver. Eur J Biochem 1992; 205: 809-14.

7. Senn HJ, Orth M, Fitzke E, Wieland H, Gerok W. Gangliosides in normal human serum. Concentration, pattern and transport by lipoproteins. Eur J Biochem 1989; 181: 657-62.

8. Senn HJ, Orth M, Fitzke E, Schölmerich J, Köster W, Wieland H, Gerok W. Altered concentrations, pattern and distribution in lipoproteins of serum gangliosides in liver diseases of different etiologies. J Hepatol 1990; 11: 290-6.

9. Katopodis N, Stock CC. Improved method to determine lipid- bound sialic acid in plasma or serum. Res Commun Chem Pathol Pharmacol 1980; 30: 171-80.

10. Schutter EM, Visser JJ, van Kamp GJ, Mensdorff-Pouilly S, van Dijk W, Hilgers J, et al. The utility of lipid-associated sialic acid (LASA or LSA) as a marker for malignancy. A review of the literature. Tumor Biol 1992; 13: 121-32.

11. Arif S, Haq N, Hanif R, Khan AS, Rehman J, Mufti TA. Variations of serum sialic acid level in liver cirrhosis. J Ayub Med Coll Abbottabad 2005; 17: 54-7.

12. Matsuzaki S, Itakura M, Iwamura K, Kamiguchi H. Serum sialic acid levels in liver cirrhosis and liver cancer. Jpn J Gastro-Enterol 1981; 78: 2395-401.

13. Seidel D. Lipoproteins in liver disease. J Clin Chem Clin Biochem 1987; 25: 541-51.

14. Dabelic S, Flögel M, Maravic G, Lauc G. Stress causes tissue- specific changes in the sialyltransferase activity. Z Naturforsch C 2004; 59: 276-80.

15. Stefenelli N, Klotz H, Engel A, Bauer P. Serum sialic acid in malignant tumors, bacterial infections, and chronic liver diseases. J Cancer Res Clin Oncol 1985; 109: 55-9.

16. Cylwik B, Chrostek L, Panasiuk A, Szmitkowski M. Serum total and free sialic acid in patients with chronic liver disease. Clin Chem Lab Med 2010; 48: 137-9.